Cargando…
Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711
BACKGROUND: Cathepsin K is an attractive therapeutic target for diseases in which bone resorption is excessive such as osteoporosis and osteoarthritis (OA). The current paper characterized the pharmacological profile of the potent and selective cathepsin K inhibitor, MIV-711, in vitro and in cynomol...
Autores principales: | Lindström, Erik, Rizoska, Biljana, Henderson, Ian, Terelius, Ylva, Jerling, Markus, Edenius, Charlotte, Grabowska, Urszula |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944028/ https://www.ncbi.nlm.nih.gov/pubmed/29743078 http://dx.doi.org/10.1186/s12967-018-1497-4 |
Ejemplares similares
-
The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of osteoarthritis
por: Lindström, Erik, et al.
Publicado: (2018) -
Analgesic effects of the cathepsin K inhibitor L-006235 in the monosodium iodoacetate model of osteoarthritis pain
por: Nwosu, Lilian N., et al.
Publicado: (2018) -
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
por: Pollack, Pia S., et al.
Publicado: (2017) -
Validation and recalibration of OxMIV in predicting violent behaviour in patients with schizophrenia spectrum disorders
por: Lamsma, Jelle, et al.
Publicado: (2022) -
Nonclinical Safety Pharmacology Study of the Herbal Product HAD-B1
por: Kim, Soo-Dam, et al.
Publicado: (2021)